Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07086469 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Toripalimab
Surufatinib
Neoadjuvant Immunochemotherapy
Chemoradiotherapy
Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Neoadjuvant immunochemotherapy
DRUG: Surufatinib Administration
DRUG: Concurrent Chemotherapy
RADIATION: Radiotherapy

Sponsor

Sun Yat-sen University